Pfizer Inc. (NYSE:PFE) Shares Acquired by Asset Management Group Inc.

Asset Management Group Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 1.7% in the third quarter, HoldingsChannel.com reports. The firm owned 51,878 shares of the biopharmaceutical company’s stock after purchasing an additional 875 shares during the quarter. Asset Management Group Inc.’s holdings in Pfizer were worth $1,501,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in Pfizer during the first quarter worth about $315,000. Edgestream Partners L.P. acquired a new position in shares of Pfizer in the 1st quarter worth approximately $243,000. Stonebridge Capital Advisors LLC raised its holdings in shares of Pfizer by 35.2% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 6,921 shares in the last quarter. Gamco Investors INC. ET AL lifted its stake in Pfizer by 123.9% during the first quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock valued at $14,798,000 after purchasing an additional 295,139 shares during the last quarter. Finally, Gabelli Funds LLC boosted its holdings in Pfizer by 23.1% during the first quarter. Gabelli Funds LLC now owns 710,413 shares of the biopharmaceutical company’s stock worth $19,714,000 after buying an additional 133,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PFE shares. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.06 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business’s 50-day moving average price is $28.28 and its two-hundred day moving average price is $28.58. The company has a market capitalization of $142.03 billion, a P/E ratio of 33.87, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is presently 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.